Results 11 to 20 of about 16,707 (188)
Analysis of a Novel Immune Checkpoint, Siglec-15, in Pancreatic Ductal Adenocarcinoma
Siglec‐15, a novel immune checkpoint, is an emerging target for next‐generation cancer immunotherapy. However, the role of Siglec‐15 in pancreatic ductal adenocarcinoma (PDAC) remains poorly understood. We investigated the expression of Siglec‐15 and its
Jie Chen, Shuangni Yu, Yue Zhang
exaly +2 more sources
Sickle red blood cell/Siglec-9 interactions contribute to neutrophil activation in SCD and are associated with survival [PDF]
: Sialic acid-binding immunoglobulin-like lectin-9 (Siglec-9) is a neutrophil inhibitory receptor. Prior studies have shown that sickle red blood cells (SS RBCs) abnormally engage neutrophil Siglec-9, suggesting that SS RBCs may not be able to ...
Grace M. Lee +4 more
doaj +2 more sources
Siglec-E is a murine CD33-related siglec that functions as an inhibitory receptor and is expressed mainly on neutrophils and macrophage populations. Recent studies have suggested that siglec-E is an important negative regulator of lipopolysaccharide (LPS)
Paul R. Crocker +2 more
exaly +3 more sources
Siglec‐15, a novel immune suppressor, is upregulated in many human cancers. The aim of this study was to explore the expression of Siglec‐15 in colorectal cancer (CRC), and investigate whether Siglec‐15 could be a potential target for cancer ...
Bingzhi Wang, Pu Cheng, Zhao Lu
exaly +2 more sources
Siglec-E retards atherosclerosis by inhibiting CD36-mediated foam cell formation [PDF]
Background The accumulation of lipid-laden macrophages, foam cells, within sub-endothelial intima is a key feature of early atherosclerosis. Siglec-E, a mouse orthologue of human Siglec-9, is a sialic acid binding lectin predominantly expressed on the ...
Yaw-Wen Hsu +7 more
doaj +2 more sources
Siglec-15 and its glycan ligands in tumor-associated macrophage biology and immunotherapy [PDF]
Siglec-15 has recently emerged as an important regulator at the interface of glyco-immunology and cancer-immunology. The transmembrane immune receptor links cancer-associated glycosylation to immune suppression in the tumor microenvironment (TME). Siglec-
Romana T Netea-Maier +6 more
doaj +2 more sources
Siglec-9 is an MHC-independent inhibitory receptor selectively expressed on CD56dim NK cells. Its role in infection diseases has not been investigated yet.
Chunhong Ma, Lifen Gao, Xueen Li
exaly +3 more sources
Sialylated glycoproteins suppress immune cell killing by binding to Siglec-7 and Siglec-9 in prostate cancer [PDF]
Prostate cancer is the second leading cause of male cancer death in the U.S. Current immune checkpoint inhibitor–based immunotherapies have improved survival for many malignancies; however, they have failed to prolong survival for prostate cancer ...
Ru M. Wen +16 more
doaj +2 more sources
Siglec-9 is an MHC-independent inhibitory receptor expressed on a subset of natural killer (NK) cells. Siglec-9 restrains NK cytotoxicity by binding to sialoglycans (sialic acid-containing glycans) on target cells.
Opeyemi S Adeniji +16 more
doaj +2 more sources
Increase of intestinal bacterial sialidase activity exacerbates acute colitis in mice
The availability of endogenous and dietary carbohydrates in the gastrointestinal tract influences the composition of the gut microbiota. Carbohydrate foraging requires the action of bacterially-encoded glycoside hydrolases, which release mono- and ...
Tobias Hasler +7 more
doaj +1 more source

